Condition
CAR T Cell
Total Trials
4
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
1Total
P 1 (1)
Trial Status
Not Yet Recruiting2
Recruiting2
Clinical Trials (4)
Showing 4 of 4 trials
NCT06839976Phase 1Recruiting
CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus
NCT07424157Not Yet RecruitingPrimary
Long-Term Follow-Up of Subjects Treated With Seattle Children's Therapeutics Gene Therapy Products
NCT06350994RecruitingPrimary
Early Assessment of Cardiac Function After Treatment With CAR-T Cells
NCT06988085Not Yet Recruiting
Impact of Lymphodepletion Regimen on the Response to CAR T-cells in Patients With With Relapsed/Refractory Large B-cell Lymphoma
Showing all 4 trials